Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women ...

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...

Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined. The biopharma's ...

Gilead Sciences (Nasdaq: GILD) reported flat revenues for the first quarter of 2025, with total sales reaching $6.7 billion, ...

Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of ...

Gilead Sciences offers steady dividend growth with a 2.99% yield. Read why the analyst nonetheless has a neutral rating on ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...